Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney Disease
Tests orforglipron against placebo for heart problems in adults with artery or kidney disease.
Key facts
- Who runs it
- Eli Lilly and Company
- Where
- Cape Town, Johannesburg, Paarl, Sommerset West, and Worcester, South AfricaSee the 5 sitesAlso in 38 other countries, 553 sites
- Trial code
- NCT07241390
- EU 2025-523123-22-00
- U1111-1326-0582
- Registry title
- A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 7,140 people, planned
- Started
- 1 Dec 2025
- Expected to end
- Aug 2031
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Orforglipron
- Placebo
- Record updated
- 4 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with established atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). It compares orforglipron with placebo and lasts about 5 years.
- Age
- 50 years or older
- Sex
- All sexes can join
- Disease stage
- Established ASCVD and/or CKD
Main reasons for not taking part
- Type 1 diabetes
- A major heart condition within 60 days before screening
- New York Heart Association Class IV heart failure
The registry criteria, word for word
Show all 4 criteriaShow less
Who can take part
- Have established ASCVD and/or CKD
Who cannot take part
- Have had a major heart condition within 60 days prior to screening
- Have type 1 diabetes
- Have New York Heart Association Functional Classification Class IV heart failure
This trial is currently available in South Africa.
Also in 38 other countries, 553 sites
- Tread ResearchCape Town, South AfricaContact: Hans Prozesky (principal investigator)Taking people
- Soweto Clinical Trials CentreJohannesburg, South AfricaContact: Qasim Bhorat (principal investigator)Not yet recruiting
- Paarl Research CentrePaarl, South AfricaContact: Kathleen Coetzee (principal investigator)Taking people
- Mediclinic VergelegenSommerset West, South AfricaContact: Johannes Engelbrecht (principal investigator)Taking people
- Clinical Projects ResearchWorcester, South AfricaContact: Louis Van Zyl (principal investigator)Taking people
About the trial
What the trial wants to find out
The purpose of this study is to measure cardiovascular outcomes with orforglipron compared with placebo in participants with atherosclerotic cardiovascular disease (ASCVD) and/or chronic kidney disease (CKD). Participation in the study will last about 5 years.
The 2 groups in the trial
- OrforglipronTreatment being tested
Participants will receive orforglipron orally + standard of care
- PlaceboPlacebo, for comparison
Participants will receive placebo orally + standard of care
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
- Plain-language title
- Orforglipron and Heart Events in People With Heart Artery Disease or Chronic Kidney DiseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 4 November 2026